海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002099 海翔药业

已收盘 10-13 15:00:00

{"stockData":{"symbol":"002099","market":"SZ","secType":"STK","nameCN":"海翔药业","latestPrice":6.11,"timestamp":1791874980000,"preClose":6.12,"halted":0,"volume":23489581,"delay":0,"changeRate":-0.0016,"floatShares":1617000000,"shares":1619000000,"eps":-0.1046,"marketStatus":"已收盘","change":-0.01,"latestTime":"10-13 15:00:00","open":6.05,"high":6.14,"low":5.89,"amount":141000000,"amplitude":0.0408,"askPrice":6.12,"askSize":787,"bidPrice":6.11,"bidSize":31,"shortable":0,"etf":0,"ttmEps":-0.1046,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791941400000},"marketStatusCode":5,"adr":0,"adjPreClose":6.12,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":6.73,"lowLimit":5.51,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1618715253,"isCdr":false,"pbRate":2.07,"roa":"--","roe":"--","epsLYR":-0.06,"committee":-0.318344,"marketValue":9890000000,"turnoverRate":0.0145,"status":1,"floatMarketCap":9879000000},"requestUrl":"/m/hq/s/002099","defaultTab":"news","newsList":[{"id":"2675804837","title":"股市必读：海翔药业(002099)股东户数3.41万户，较上期增加1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675804837","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675804837?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:24","pubTimestamp":1791825855,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘，海翔药业报收于6.12元，下跌3.16%，换手率1.46%，成交量23.57万手，成交额1.46亿元。股本股东变化：截至2026年10月9日，海翔药业股东户数为3.41万户，较9月18日增加650.0户，增幅1.94%。户均持股数量由上期的4.84万股减少至4.75万股，户均持股市值为30.02万元。谢谢董秘： 您好，公司9月30日股东人数请关注公司后续披露的《2026年三季度报告》。截至10月9日公司股东人数为34082人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","002099","BK0028","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674827688","title":"海翔药业：截至10月9日公司股东人数为34082人","url":"https://stock-news.laohu8.com/highlight/detail?id=2674827688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674827688?lang=zh_cn&edition=full","pubTime":"2026-10-12 15:42","pubTimestamp":1791790931,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)10月12日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至9月30日和10月10日公司股东人数分别是多少？谢谢海翔药业回复：您好，公司9月30日股东人数请关注公司后续披露的《2026年三季度报告》。截至10月9日公司股东人数为34082人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200015858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0077","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674200199","title":"股市必读：海翔药业新发布《关于股份回购进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674200199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674200199?lang=zh_cn&edition=full","pubTime":"2026-10-09 01:02","pubTimestamp":1791478935,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘，海翔药业报收于6.15元，上涨0.0%，换手率2.39%，成交量38.57万手，成交额2.4亿元。公司公告汇总：截至2026年9月30日，海翔药业已回购股份24,161,073股，占总股本1.49%，成交总金额1.228亿元。公司公告汇总关于股份回购进展情况的公告浙江海翔药业股份有限公司于2026年6月22日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金以集中竞价交易方式回购公司股票，用于未来股权激励或员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900001399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0077","BK0188","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673049054","title":"海翔药业（002099）9月30日主力资金净买入1495.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673049054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673049054?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:08","pubTimestamp":1791421739,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，海翔药业报收于6.15元，上涨2.5%，换手率2.07%，成交量33.43万手，成交额2.06亿元。近5日资金流向一览见下表：海翔药业融资融券信息显示，融资方面，当日融资买入1485.61万元，融资偿还1232.42万元，融资净买入253.18万元，连续3日净买入累计1043.47万元。海翔药业主营业务：公司医药板块业务涉及特色原料药及医药中间体、仿制药的研发和商业化生产销售,并为全球知名制药企业提供定制研发及生产服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800003034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002099","BK0077","BK0028","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269014","title":"海翔药业（002099）9月28日主力资金净买入398.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269014?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:04","pubTimestamp":1790643859,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，海翔药业报收于6.0元，上涨3.09%，换手率3.08%，成交量49.85万手，成交额3.0亿元。近5日资金流向一览见下表：海翔药业融资融券信息显示，融资方面，当日融资买入1314.12万元，融资偿还1165.04万元，融资净买入149.08万元。海翔药业主营业务：公司医药板块业务涉及特色原料药及医药中间体、仿制药的研发和商业化生产销售,并为全球知名制药企业提供定制研发及生产服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900008166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0188","002099","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670828395","title":"海翔药业：截至9月18日公司股东人数为33432人","url":"https://stock-news.laohu8.com/highlight/detail?id=2670828395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670828395?lang=zh_cn&edition=full","pubTime":"2026-09-28 11:33","pubTimestamp":1790566383,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月28日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司九月十八日的股东人数，谢谢海翔药业回复：您好，截至9月18日公司股东人数为33432人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800010179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","002099","BK0077","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409865","title":"股市必读：海翔药业新发布《关于为合并报表范围内子公司提供担保的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409865?lang=zh_cn&edition=full","pubTime":"2026-09-28 01:12","pubTimestamp":1790529133,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，海翔药业报收于5.82元，下跌2.02%，换手率1.75%，成交量28.26万手，成交额1.65亿元。公司公告汇总：公司为全资子公司宜昌海翔药业提供430万元连带责任保证担保，担保余额为207.21万元，无逾期对外担保。本次担保在公司股东大会批准的对合并报表范围内子公司5,000万元担保额度内。截至2026年9月22日，公司对合并报表范围内子公司担保总额为23,136.39万元，担保余额为207.21万元，无逾期对外担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800000758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0192","BK0188","BK0077","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669815124","title":"股市必读：海翔药业（002099）9月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669815124","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669815124?lang=zh_cn&edition=full","pubTime":"2026-09-23 03:04","pubTimestamp":1790103854,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，海翔药业报收于5.63元，上涨2.36%，换手率1.92%，成交量31.01万手，成交额1.75亿元。董秘最新回复投资者： 你好，万邦德大股东多次挪用公司资金已经基本确认要被立案调查。目前双方合作正常。当日关注点交易信息汇总：9月22日主力资金净流出74.48万元，游资资金净流出1126.34万元，散户资金净流入1200.82万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300003179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0077","BK0188","BK0192","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711146","title":"海翔药业：目前双方合作正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669711146?lang=zh_cn&edition=full","pubTime":"2026-09-22 15:18","pubTimestamp":1790061496,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，万邦德大股东多次挪用公司资金已经基本确认要被立案调查。海翔支付给万邦德的1.2亿预付款是否正常应用在药品研发还是被挪用？海翔有没有监控预付款的使用情况？请正面回答股东问题，谢谢。海翔药业回复：您好，根据双方签订的《创新药合作协议》：万邦德以自有团队和资源，具体实施WP205产品研发、上市、授权、销售等各项工作。公司按照约定提供资金并取得相关收益。目前双方合作正常。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200020865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0192","BK0077","BK0239","BK0028","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669153321","title":"海翔药业：截至9月10日公司股东人数为33219人","url":"https://stock-news.laohu8.com/highlight/detail?id=2669153321","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669153321?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:07","pubTimestamp":1789974438,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月21日在投资者关系平台上答复投资者关心的问题。投资者提问：截至9月10日公司股东人数为多少？海翔药业回复：您好，截至9月10日公司股东人数为33219人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100013446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002099","BK0028","BK0192","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608204","title":"海翔药业：截至8月31日公司股东人数为33675人","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608204?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:07","pubTimestamp":1789542445,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司截止9月31日股东人数是多少？谢谢！海翔药业回复：您好，截至8月31日公司股东人数为33675人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600018788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0239","BK0188","BK0028","BK0077","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372594","title":"股市必读：海翔药业(002099)股东户数3.37万户，较上期增加5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372594","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666372594?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:31","pubTimestamp":1788888672,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，海翔药业报收于5.46元，下跌0.18%，换手率0.89%，成交量14.44万手，成交额7893.03万元。当日关注点交易信息汇总：9月8日主力资金净流出827.43万元，占总成交额10.48%。股本股东变化：截至2026年8月31日，海翔药业股东户数为3.37万户，较8月10日增长5.77%。户均持股数量由上期的5.08万股减少至4.81万股，户均持股市值为27.11万元。投资者： 请问截止9月5日，公司股东人数是多少？董秘： 您好，截至8月31日公司股东人数为33675人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0028","BK0077","BK0239","BK0192","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665345044","title":"海翔药业：截至8月31日公司股东人数为33675人","url":"https://stock-news.laohu8.com/highlight/detail?id=2665345044","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665345044?lang=zh_cn&edition=full","pubTime":"2026-09-08 09:09","pubTimestamp":1788829764,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业(002099)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司到八月底的股东人数，谢谢海翔药业回复：您好，截至8月31日公司股东人数为33675人。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800006372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","002099","BK0188","BK0239","BK0192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664457718","title":"股市必读：海翔药业新发布《关于股份回购进展情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664457718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664457718?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:28","pubTimestamp":1788373691,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，海翔药业报收于5.43元，下跌3.04%，换手率1.3%，成交量21.06万手，成交额1.15亿元。当日关注点交易信息汇总：9月2日主力资金净流入207.29万元，占总成交额1.81%。公司公告汇总：截至2026年8月31日，海翔药业已回购股份24,161,073股，占总股本1.49%，成交总金额1.228亿元，回购进展符合既定方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0192","BK0239","BK0077","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664524108","title":"海翔药业（002099）披露股份回购进展公告，9月1日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664524108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664524108?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:14","pubTimestamp":1788272086,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，海翔药业报收于5.6元，较前一交易日下跌0.71%，最新总市值为90.65亿元。该股当日开盘5.75元，最高5.95元，最低5.53元，成交额达2.03亿元，换手率为2.21%。近日，海翔药业发布《关于股份回购进展情况的公告》。公告显示，公司于2026年6月22日召开董事会，审议通过回购股份方案，拟使用自有/自筹资金以集中竞价交易方式回购公司股份，用于未来股权激励或员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100042690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0192","BK0028","BK0077","002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663204826","title":"海翔药业（002099）2026年中报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663204826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663204826?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:23","pubTimestamp":1788042184,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期海翔药业发布2026年中报。截至本报告期末，公司营业总收入10.23亿元，同比上升10.56%，归母净利润-6403.8万元，同比下降554.37%。本报告期海翔药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达45.06%。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司现金流状况本文数据来源于海翔药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0239","BK0192","BK0188","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098892","title":"海翔药业(002099.SZ)发布半年度业绩，归母净亏损6403.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098892","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662098892?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:13","pubTimestamp":1787919206,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业(002099.SZ)发布2026年半年度报告，报告期内，公司实现营业收入10.23亿元，同比增长10.56%;实现归属于上市公司股东的净亏损6403.8万元，同比由盈转亏;归属于上市公司股东的扣除非经常性损益的净亏损1.24亿元，同比由盈转亏;基本每股收益-0.04元。2026年上半年，公司紧紧围绕年度经营目标，扎实推进研发、生产、销售、注册及质量等各项工作，经营运行总体保持平稳。公司加大BD拓展力度，积极参加美国、上海、日本、孟加拉等各类医药、染料展会，持续开拓新客户、新项目，为未来发展做好项目储备。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"海翔药业(002099.SZ)发布半年度业绩，归母净亏损6403.8万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002099","BK0188","BK0077","BK0192","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662106126","title":"图解海翔药业中报：第二季度单季净利润同比下降1960.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662106126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662106126?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:24","pubTimestamp":1787912650,"startTime":"0","endTime":"0","summary":"证券之星消息，海翔药业2026年中报显示，上半年度公司主营收入10.23亿元，同比上升10.56%；归母净利润-6403.8万元，同比下降554.37%；扣非净利润-1.24亿元，同比下降744.73%；其中2026年第二季度，公司单季度主营收入5.36亿元，同比上升22.25%；单季度归母净利润-9048.44万元，同比下降1960.38%；单季度扣非净利润-8108.01万元，同比下降734.99%；负债率33.02%，投资收益5161.34万元，财务费用3448.94万元，毛利率22.56%。财报数据概要请见下图:本文数据来源于海翔药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662406618","title":"海翔药业(002099)8月10日股东户数3.18万户，较上期减少7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662406618","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662406618?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:46","pubTimestamp":1787910388,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海翔药业披露，截至2026年8月10日公司股东户数为3.18万户，较6月18日减少2396.0户，减幅为7.0%。在化学制药行业个股中，海翔药业股东户数低于行业平均水平，截至8月10日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年6月18日至2026年8月10日，海翔药业区间涨幅为8.84%，在此期间股东户数减少2396.0户，减幅为7.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002099","BK0028","BK0077","BK0239","BK0192","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791049","title":"海翔药业最新公告：全资子公司获环磷腺苷原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791049","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662791049?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:26","pubTimestamp":1787736380,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司全资子公司浙江海翔川南药业有限公司收到国家药监局核准签发的环磷腺苷《化学原料药上市申请批准通知书》。环磷腺苷为血管舒张药，用于心绞痛、心肌梗死等。该原料药尚需通过GMP符合性检查后方可生产销售，短期内不会对公司业绩产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0192","BK0028","002099","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791923660685,"stockEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":0.155},{"period":"3month","weight":0.1594},{"period":"6month","weight":-0.137},{"period":"1year","weight":0.0589},{"period":"ytd","weight":-0.0208}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0628},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.0423}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海翔药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34082人(较上一季度增加1.94%)","perCapita":"47439股","listingDate":"2006-12-26","address":"浙江省台州市椒江区外沙支路100号","registeredCapital":"161871万元","survey":"　　浙江海翔药业股份有限公司的主营业务是原料药及医药中间体、染料及染颜料中间体的研发、生产和销售。公司的主要产品是原料药、医药中间体、合同定制、制剂、染料、染颜料中间体。公司企业技术中心被认定为“国家级企业技术中心”，拥有国家级博士后工作站，建有川南药业省级重点企业研究院以及海翔药业和台州前进两个省级企业研究院，并在上海设立负责医药研发的独立子公司，建有2400m²实验室。已承担完成国家级项目15项，省级项目35项，拥有国内发明专利67项、PCT专利5项，荣获浙江省级科技奖项11项。","listedPrice":11.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海翔药业,002099,海翔药业股票,海翔药业股票老虎,海翔药业股票老虎国际,海翔药业行情,海翔药业股票行情,海翔药业股价,海翔药业股市,海翔药业股票价格,海翔药业股票交易,海翔药业股票购买,海翔药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海翔药业(002099)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海翔药业(002099)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}